Seo Salimi is a partner in Goodwin's Technology Companies & Life Sciences group. His practice focuses on corporate transactions and securities laws with a particular emphasis on representing clients in public and private capital markets transactions such as initial public offerings, follow-on offerings and private placements of equity and debt securities. He also represents public and private companies in their ongoing corporate matters, including SEC compliance and corporate governance. His clients include global investment banks and domestic and foreign issuers. His experience extends to a variety of industries, with a focus on the life science sector.

Areas of Practice
Domaines D’Expertise





A selection of Mr. Salimi’s recent representations include:

Domestic Representations 

  • Karuna Therapeutics, Inc. in its $100 million initial public offering
  • Surface Oncology, Inc. in its $110 million initial public offering and $11.5 million concurrent private placement
  • HOOKIPA Pharma Inc. in its $85 million initial public offering
  • Goldman Sachs and JP Morgan as underwriters in over $1.5 billion of equity offerings by Sarepta Therapeutics, Inc.
  • Goldman Sachs and JP Morgan as underwriters in a $610 million initial public offering by Switch, Inc.
  • Citigroup as underwriter in multiple life science initial public offerings and follow-on offerings
  • Cowen and Company, as underwriter in multiple life science initial public offerings and follow-on offerings

Cross-Border Representations

  • Ablynx NV in its $230 U.S. initial public offering (Country of Issuer: Belgium)
  • CRISPR Therapeutics AG in its initial public offering and follow-on financings (Country of Issuer: Switzerland)
  • Goldman Sachs, Morgan Stanley and other underwriters in over $400 million of equity offerings by DBV Technologies (Country of Issuer: France)
  • Underwriting syndicates in $70 million initial public offering by AC Immune SA and $100 million follow-on offering (Country of Issuer: Switzerland)
  • Leerink Partners in a $140 million public offering by Aurinia Pharmaceuticals Inc. (Country of Issuer: Canada)
Professional Experience

Prior to joining Goodwin, Mr. Salimi was an associate at Latham & Watkins LLP and later served as the general counsel of a NASDAQ listed company. 

In The News









J.D., 2004
University of Southern California, Gould School of Law
B.A., 2001
University of California, Irvine



New York
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.


Search Other Lawyers
Recherche par Pratique